

## Quick reference summary

### Guidelines

Relevant clinical practice guidelines are listed below.

### Specific recommendations available for the HIV population

- European AIDS Clinical Society (EACS) [Guidelines. Version 6.0.](#)\* [Accessed 03 July 2012]
- Dubé MP, Stein JH, Aberg JA, et al. [Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus \(HIV\)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.](#)\* *Clin Infect Dis.* 2003;37:613–627.
- Glesby M, Lee D, Armas L, et al. [Managing Dyslipidemia in HIV: A Comprehensive Tool for the Primary Care Clinician.](#)\* 2008. [Accessed 09 August 2011]

### Specific recommendations available for the general population

- The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). [ESC/EAS Guidelines for the Management of Dyslipidemias.](#)\* *Eur Heart J.* 2011;32:1769–1818.
- National Institutes of Health, National Heart, Lung and Blood Institute. [Third report of the National Cholesterol Education Program \(NCEP\) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults \(Adult Treatment Panel III \[ATP III\]\).](#)\* [Accessed 05 August 2011]

### Key Publications

Treatment guidelines, such as those provided by the [European AIDS Clinical Society \(EACS\)](#) and the [Infectious Disease Society of America \(IDSA\) / Adult AIDS Clinical Trials Group \(ACTG\)](#)\* are key resources for the management of dyslipidemia.

### Additional reading

#### HIV infection and lipids

- Grunfeld C, Pang M, Doerrler W, et al. [Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.](#)\* *J Clin Endocrinol Metab.* 1992;74:1045–1052.
- Grinspoon S. [Diabetes mellitus, cardiovascular risk, and HIV disease.](#)\* *Circulation.* 2009;119:770–772. [Review]
- Grinspoon SK. [Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.](#)\* *Am J Med.* 2005;118 Suppl 2:23S–28S. [Review]
- Grunfeld C. [Dyslipidemia and its treatment in HIV Infection.](#)\* *Top HIV Med.* 2010;18:112–118. [Review]

- Tarr PE, Rotger M, Telenti A. [Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics](#).\* *Pharmacogenomics*. 2010;11:587–594. [Review]

### Antiretroviral therapy and lipids

- Fontas E, van Leth F, Sabin CA, et al. [Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?](#)\* *J Infect Dis*. 2004;189:1056–1074.
- Mulligan K, Grunfeld C, Tai VW, et al. [Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection](#).\* *J Acquir Immune Defic Syndr*. 2000;23:35–43.
- Nery MW, Martelli CM, Turchi MD. [Dyslipidemia in AIDS patients on highly active antiretroviral therapy](#).\* *Braz J Infect Dis*. 2011;15:151–155.
- Périard D, Telenti A, Sudre P, et al. [Atherogenic dyslipidaemia in HIV-infected individuals treated with protease inhibitors](#).\* The Swiss HIV Cohort Study. *Circulation*. 1999;100:700–705.
- Riddler SA, Smit E, Cole SR, et al. [Impact of HIV infection and HAART on serum lipids in men](#).\* *JAMA*. 2003;289:2978–2982.
- Feeney ER and Mallon PW. [HIV and HAART-associated dyslipidemia](#).\* *Open Cardiovasc Med J*. 2011;5:49–63. [Review]
- Tungsiripat M, Aberg JA. [Dyslipidaemia in HIV patients](#).\* *Cleve Clin J Med*. 2005;72:1113–1120. [Review]